ATE527237T1 - Modifizierter mscl-proteinkanal - Google Patents

Modifizierter mscl-proteinkanal

Info

Publication number
ATE527237T1
ATE527237T1 AT04808728T AT04808728T ATE527237T1 AT E527237 T1 ATE527237 T1 AT E527237T1 AT 04808728 T AT04808728 T AT 04808728T AT 04808728 T AT04808728 T AT 04808728T AT E527237 T1 ATE527237 T1 AT E527237T1
Authority
AT
Austria
Prior art keywords
channel
light
responsive
compounds
protein channel
Prior art date
Application number
AT04808728T
Other languages
English (en)
Inventor
Armagan Kocer
Martin Walko
George Robillard
Original Assignee
Applied Nanosystems Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Nanosystems Bv filed Critical Applied Nanosystems Bv
Application granted granted Critical
Publication of ATE527237T1 publication Critical patent/ATE527237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/04—Thiosulfonates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04808728T 2003-11-25 2004-11-25 Modifizierter mscl-proteinkanal ATE527237T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078718A EP1535903A1 (de) 2003-11-25 2003-11-25 Modifizierter MSCL-Protein-Kanal
PCT/NL2004/000812 WO2005051902A2 (en) 2003-11-25 2004-11-25 MODIFIED MscL PROTEIN CHANNEL

Publications (1)

Publication Number Publication Date
ATE527237T1 true ATE527237T1 (de) 2011-10-15

Family

ID=34442990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04808728T ATE527237T1 (de) 2003-11-25 2004-11-25 Modifizierter mscl-proteinkanal

Country Status (5)

Country Link
US (2) US7393828B2 (de)
EP (2) EP1535903A1 (de)
AT (1) ATE527237T1 (de)
DK (1) DK1687267T3 (de)
WO (1) WO2005051902A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1535903A1 (de) 2003-11-25 2005-06-01 Applied NanoSystems B.V. Modifizierter MSCL-Protein-Kanal
EP1832575A1 (de) * 2006-03-06 2007-09-12 Sulfidris S.r.l. Entzündungshemmende Mittel
US20100189777A1 (en) * 2007-07-20 2010-07-29 Basf Se Functionalized nanocompartments with a transport system
US8227204B2 (en) 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8684898B2 (en) 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8164074B2 (en) 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8529426B2 (en) 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
EP2127640A1 (de) * 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Modifizierte azid-enthaltende Proteine
RU2531639C2 (ru) 2009-06-24 2014-10-27 Конинклейке Филипс Электроникс Н.В. Способ и устройство для программирования микроконтроллера
PL213159B1 (pl) 2010-04-23 2013-01-31 Inst Biolog Doswiadczalnej Im Marcelego Nenckiego Pan Zmutowane szczepy Escherichia coli, sposób testowania potencjalnych zwiazków antybakteryjnych wykorzystujacy te szczepy oraz zestaw do testowania
WO2014081300A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
CN111801232B (zh) * 2018-01-29 2023-12-15 法雷奥气候控制公司 用于电动车辆的hvac模块
US12583885B2 (en) * 2020-11-13 2026-03-24 Cornell University Compositions of hybrid supported lipid bilayers and methods for producing
CN115902186A (zh) * 2021-08-30 2023-04-04 四川大学 一种基于MtMscL纳米孔的孔膜复合体及其应用
CN114854431B (zh) * 2022-05-24 2023-06-13 江南大学 一种基于动态共价键的智能Pickering乳状液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2743260A (en) * 1953-05-25 1956-04-24 Us Rubber Co Polymeric methyeol maleimide and derivatives
NL247005A (de) * 1959-01-05
DE2100440A1 (de) * 1971-01-07 1972-07-20 Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt Maleinimide und Verfahren zu ihrer Herstellung
US4011327A (en) * 1975-01-31 1977-03-08 Research Corporation Compositions containing 7β-alkylthiodeoxynupharadin-6α-ols
EP1535903A1 (de) 2003-11-25 2005-06-01 Applied NanoSystems B.V. Modifizierter MSCL-Protein-Kanal

Also Published As

Publication number Publication date
US20060258587A1 (en) 2006-11-16
WO2005051902A8 (en) 2005-08-11
DK1687267T3 (da) 2012-01-23
EP1687267B1 (de) 2011-10-05
WO2005051902A3 (en) 2005-10-27
EP1687267A2 (de) 2006-08-09
US7608582B2 (en) 2009-10-27
US7393828B2 (en) 2008-07-01
EP1535903A1 (de) 2005-06-01
WO2005051902A2 (en) 2005-06-09
US20080138401A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
DK1687267T3 (da) Modificeret MscL-proteinkanal
WO2005046709A3 (en) Tgf - beta binding and supported peptides
MY154826A (en) Fusion protein capable of binding vegf
ATE360031T1 (de) Chimäre proteine und anwendungen
DE602004019965D1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
CY1108673T1 (el) Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
ATE397016T1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2006000213A3 (de) Peptide zur inhibition der interaktion von proteinkinase a und proteinkinase a-ankerproteinen
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2006047728A3 (en) Bmp gene and fusion protein
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2004050014A3 (en) Seterocyclic quinones as pharmaceutical agents
WO2005062767A3 (en) Hoxd3, hoxa3, and hoxb3 compositions and methods for improved wound healing
DOP2006000117A (es) Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
WO2006018450A3 (en) Pharmaceutically active insulin receptor-modulating molecules
WO2005016247A3 (en) Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
AU2004206257A8 (en) Human SAA3 nucleic acid molecule, protein, and methods of use for same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties